We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Clarifies Procedure for Reporting Deviations in Biologics Manufacturing
FDA Clarifies Procedure for Reporting Deviations in Biologics Manufacturing
November 15, 2006
In an effort to help biologic product manufacturers report deviations from current good manufacturing practices (cGMPs), the FDA issued a guidance detailing the correct steps to take when an event occurs that may affect the safety, purity or potency of products.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor